These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 16396776)

  • 1. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
    Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
    Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
    Guo Z; Meng M; Geng S; Du Z; Zheng Y; Yao J; Li Z; Han G; Lin H; Du G
    J Ethnopharmacol; 2017 Jan; 196():29-38. PubMed ID: 27965050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
    Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
    Leukemia; 2013 Feb; 27(2):315-24. PubMed ID: 22751450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
    Wang R; Liu C; Xia L; Zhao G; Gabrilove J; Waxman S; Jing Y
    Clin Cancer Res; 2012 Dec; 18(24):6690-701. PubMed ID: 23082001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells.
    Duechler M; Stańczyk M; Czyz M; Stepnik M
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):727-37. PubMed ID: 17594095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
    Tanaka Y; Komatsu T; Shigemi H; Yamauchi T; Fujii Y
    BMC Cancer; 2014 Jan; 14():27. PubMed ID: 24428916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.
    Kumar S; Yedjou CG; Tchounwou PB
    J Exp Clin Cancer Res; 2014 May; 33(1):42. PubMed ID: 24887205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status.
    Huang MJ; Hsieh RK; Lin CP; Chang IY; Liu HJ
    Leuk Lymphoma; 2002 Nov; 43(11):2191-9. PubMed ID: 12533046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
    Ramos AM; Aller P
    Biochem Pharmacol; 2008 May; 75(10):1912-23. PubMed ID: 18359480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
    Golemovic M; Quintás-Cardama A; Manshouri T; Orsolic N; Duzkale H; Johansen M; Freireich EJ; Kantarjian H; Zingaro RA; Verstovsek S
    Invest New Drugs; 2010 Aug; 28(4):402-12. PubMed ID: 19468689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.
    Aldoss I; Mark L; Vrona J; Ramezani L; Weitz I; Mohrbacher AM; Douer D
    Ann Hematol; 2014 Nov; 93(11):1839-43. PubMed ID: 24906216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
    Konig H; Härtel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; La Rosée P
    Haematologica; 2007 Jun; 92(6):838-41. PubMed ID: 17550858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
    Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
    Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
    Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J
    Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.
    Konopleva M; Konoplev S; Hu W; Zaritskey AY; Afanasiev BV; Andreeff M
    Leukemia; 2002 Sep; 16(9):1713-24. PubMed ID: 12200686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
    Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
    Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 mediates ATO-induced apoptosis in acute myeloid leukemia cell lines through the Wnt signaling pathway.
    Zhang H; Gu H; Li L; Ren Y; Zhang L
    Tumour Biol; 2016 May; 37(5):5919-23. PubMed ID: 26592252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
    Parmar S; Rundhaugen LM; Boehlke L; Riley M; Nabhan C; Raji A; Frater JL; Tallman MS
    Leuk Res; 2004 Sep; 28(9):909-19. PubMed ID: 15234567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.